Tech Company Financing Transactions
4Moving Biotech Funding Round
Private investors participated in a $14 million funding round for 4Moving Biotech. The round closed on 2/10/2026.
Transaction Overview
Company Name
Announced On
2/10/2026
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 rue du Professeur Calmette, Campus de l'Institut Pasteur d
Lille, 59000
France
Lille, 59000
France
Phone
Undisclosed
Website
Email Address
Overview
4Moving Biotech is a cutting-edge clinical-stage company pioneering in the field of osteoarthritis (OA) research. We were inspired by the groundbreaking work of renowned rheumatologist Prof. Francis Berenbaum; our unique product, 4P004, targets low-grade inflammation using GLP-1 analogs. This innovative application of GLP-1 analogs represents a promising path toward a natural curse of the disease. By integrating advanced AI, real-world data, and innovative clinical trial design, we optimize our Phase 2 trial selection using data from 11.4 million patients, swiftly advancing treatments to those who need them most?.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Luc Boblet
Chief Financial Officer
Jérôme Vailland
Chief Marketing Officer
Francis Berenbaum
Chief Medical Officer
Odile Fleurot
Chief Operating Officer
Stéphanie Rosciglione
President
Revital Rattenbach
VP - R & D
Céline Martin
Browse more venture capital transactions:
Prev: 2/10/2026: Runway venture capital transaction
Next: 2/10/2026: xWatts venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs